Corrigendum to “Cardiovascular side-effects and insulin secretion after intravenous administration of radiolabeled Exendin-4 in pigs” [Nucl Med Biol 43 (2016) 397–402]

Rydén, Anneli; Nyman, Görel; Nalin, Lovisa; Andréasson, Susanne; Velikyan, Irina; Korsgren, Olle; Jensen-Waern, Marianne

doi:10.1016/j.nucmedbio.2016.08.013

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a preclinical PET imaging study with [ 68 Ga]Ga-DO3A-VS-Cys 40 -exendin-4, pigs developed tachycardia after intravenous administration 94, 96, however to the best of our knowledge the published patient studies did not present such adverse effects. In some patients, transient palpitation at the time of injection that lasted a few seconds has been reported 38.…”

Section: Clinical Accomplishmentsmentioning

confidence: 84%

“…Thus, the pancreatic distribution of GLP-1R seems to differ radically in pigs compared to rats, with more expression in the exocrine pancreas. Interestingly, the pigs experienced dose dependently increased heart rate after administration of [ 68 Ga]Ga-DO3A-VS-Cys 40 -exendin-4 96, 97 to a degree which usually not seen in other species. Strong pancreatic binding of [ 68 Ga]Ga-DO3A-VS-Cys 40 -exendin-4 was also observed in cynomolgus monkeys (NHP).…”

Section: Imaging Agents: Chemistry and Pre-clinical Evaluationmentioning

confidence: 91%

See 1 more Smart Citation

Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics

Velikyan

Eriksson

2020

Theranostics

Self Cite

View full text Add to dashboard Cite

In the light of theranostics/radiotheranostics and prospective of personalized medicine in diabetes and oncology, this review presents prior and current advances in the development of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like peptide-1 receptor. The review covers chemistry, preclinical, and clinical evaluation. Such critical aspects as structure-activity-relationship, stability, physiological potency, kidney uptake, and dosimetry are discussed.

show abstract

Section: Clinical Accomplishmentsmentioning

confidence: 84%

Section: Imaging Agents: Chemistry and Pre-clinical Evaluationmentioning

confidence: 91%

Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics

Velikyan

Eriksson

2020

Theranostics

Self Cite

View full text Add to dashboard Cite

show abstract

“…To our best knowledge the published patient studies did not present any cases of adverse effect such as tachycardia even though pigs developed severe tachycardia upon administration of [ 68 Ga]-DO3A-VS-Cys 40 -exendin-4 [ 81 , 82 ]. In one patient only transient palpitation at the time of injection that lasted a few seconds has been reported [ 47 ].…”

Section: Glucagon-like Peptide-1 Receptor Targetingmentioning

confidence: 99%

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms

2017

Self Cite

View full text Add to dashboard Cite

Nuclear medicine plays a pivotal role in the management of patients affected by neuroendocrine neoplasms (NENs). Radiolabeled somatostatin receptor analogs are by far the most advanced radiopharmaceuticals for diagnosis and therapy (radiotheranostics) of NENs. Their clinical success emerged receptor-targeted radiolabeled peptides as an important class of radiopharmaceuticals and it paved the way for the investigation of other radioligand-receptor systems. Besides the somatostatin receptors (sstr), other receptors have also been linked to NENs and quite a number of potential radiolabeled peptides have been derived from them. The Glucagon-Like Peptide-1 Receptor (GLP-1R) is highly expressed in benign insulinomas, the Cholecystokinin 2 (CCK2)/Gastrin receptor is expressed in different NENs, in particular medullary thyroid cancer, and the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor was found to be expressed in gastrointestinal and bronchial NENs, where interestingly, it is present in most of the sstr-negative and GLP-1R-negative NENs. Also in the field of sstr targeting new discoveries brought into light an alternative approach with the use of radiolabeled somatostatin receptor antagonists, instead of the clinically used agonists. The purpose of this review is to present the current status and the most innovative strategies for the diagnosis and treatment (theranostics) of neuroendocrine neoplasms using a cadre of radiolabeled regulatory peptides targeting their receptors.

show abstract

In VivoImaging of the Pancreas and Gut Hormone Receptors

Eriksson

Hulsart‐Billström

Mitran

et al. 2022

Nanotechnology for Diabetes Management

View full text Add to dashboard Cite

Biomedical imaging techniques like positron emission tomography (PET) have been implemented into the clinical diagnostic routine in many areas, such as oncology, neurology, and cardiology. However, their use in the clinical management of diabetes is not as advanced. Recent decades have seen progress in novel techniques for clinical molecular imaging of receptors and cell subtypes, including those crucial for pancreatic function in both health and disease. Advances include studying, e.g., the insulin-producing beta cells and the most common incretin and gut hormone receptors. Techniques for efficient functionalisation and radiolabelling of peptides and proteins have enabled PET imaging using the growing number of biological drugs or modified endogenous hormones. Importantly, the novel techniques are in or under clinical translation and approval, suggesting that they may become part of the routine assessment in diabetes diagnosis and management in the coming years. This chapter summarises recent developments and advances in the application of PET techniques for visualising processes in the pancreas that are crucial in diabetes pathology and treatment.

show abstract

Corrigendum to “Cardiovascular side-effects and insulin secretion after intravenous administration of radiolabeled Exendin-4 in pigs” [Nucl Med Biol 43 (2016) 397–402]

Cited by 3 publications

References 0 publications

Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics

Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms

In VivoImaging of the Pancreas and Gut Hormone Receptors

Contact Info

Product

Resources

About